
OMM Scientific Inc Profile last edited on: 1/12/22
CAGE: 48C04
UEI: DM23ABHM6JK1
Business Identifier: Chemistry for life sciences applications Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
2600 North Stemmons Freeway Suite 129
Dallas, TX 75207
Dallas, TX 75207
(214) 350-9156 |
info@ommscientific.com |
www.ommscientific.com |
Location: Single
Congr. District: 30
County: Dallas
Congr. District: 30
County: Dallas
Public Profile
OMM Scientific Inc., is a chemistry-based drug discovery, development and manufacturing company,focusing on marketing of specialty organic chemicals, screening libraries of synthetic and natural products and provide innovative custom solutions to pharmaceutical and chemical industries. They possess capabilities ranging from synthetic feasibility to drug discovery, process development and production. OMM Scientific's contract research capabilities include: research tool design, multi-step complex syntheses, process optimization to kg quantities, analog synthesis, SAR optimization and analytical method development. OMM Scientific also is able to offer custom synthesis of high value products for the biotech and biopharmaceutical industries. These include: eicosanoids, arachidonic acid metabolites, mitochondrial targeted conjugates, azideâalkyne chemistries and biotinylation.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
1-4Revenue Range
Less than .5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
1-4Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2016 | 2 | NIH | $438,476 | |
Project Title: Development of a Broad Spectrum Antiviral for Ebola and Marburg Viral Infections | ||||
2016 | 2 | AF | $1,349,915 | |
Project Title: Selective Oxidation of Heterocyclic Amines | ||||
2014 | 1 | Navy | $79,996 | |
Project Title: Rapid Feasibility Studies for Novel Routes to Direct CL-20 Intermediates | ||||
2013 | 1 | NIH | $249,997 | |
Project Title: Igf::Ot::Igf Development of a Vatpase Inhibitor as a Radiosensitizer | ||||
2013 | 1 | NIH | $249,997 | |
Project Title: Development of Radiation Modulators for Use During Radiotherap |
Key People / Management
Donald R Stewart -- President; Chief Executive Officer
Edward R Biehl -- Professor of Chemistry
Robert A Davey
Ignacy Gryczynski
Edward R Biehl -- Professor of Chemistry
Robert A Davey
Ignacy Gryczynski
Company News
There are no news available.